To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase 1 Completed 32 enrolled Cerevel Therapeutics, LLC

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of the study is to assess the effect of hepatic impairment on the PK of tavapadon following administration of a single oral dose in participants with mild and moderate hepatic impairment relative to age, body weight, and sex-matched participants with normal hepatic function.

Timeline

Start: 2022-04-29
Primary completion: 2023-01-24
Completion: 2023-01-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tavapadon	Small molecule	0.25 mg	Oral
Subject	Tavapadon	Small molecule	0.5 mg	Oral

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Summary

Timeline

Drugs

Indications